Phase II trial of oxaliplatin plus oral capecitabine as first-line chemotherapy for patients with advanced gastric cancer

Tumori

Volumn 97, Issue 4, 2011, Pages 466-472

  Yang, Tingsong ^a   Shen, Xiaojun ^a   Tang, Xiaojun ^b   Wei, Guo ^a   Zhang, Hao ^a   Du, Chenghui ^a   Xue, Xuchao ^a   Ma, Liye ^a   Nie, Mingming ^a   Bi, Jianwei ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Advanced gastric cancer; Capecitabine; Oxaliplatin

Indexed keywords

CAPECITABINE; CISPLATIN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHINESE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 80053652844     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161109700409     Document Type: Article

References (35)

1. Jemal A, Siegel R,Ward E, Murray T, Xu J, Thun MJ: Cancer statistics. CA Cancer J Clin, 57: 43-66, 2007.
2. Hong YS, Song SY, Cho JY, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS, Cho JY: A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol, 15: 1344-1347, 2004. (Pubitemid 39295021)
3. Park YH, Ryoo BY, Choi SJ, Kim HT: A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer, 90: 1329-1333, 2004. (Pubitemid 38586256)
4. Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Micheel S, Pink D, Scholz C, Dorken B, Reichardt P: Docetaxel and continuous-infusion fluorouracil vs epirubicin, cisplatin and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol, 23: 494-501, 2005. (Pubitemid 46237444)
5. Chang HM, Jung KH, Kim TY, Kim WS, Yang HK, Lee KU, Choe KJ, Heo DS, Bang YJ, Kim NK: A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer. Ann Oncol, 13: 1779-1785, 2002. (Pubitemid 35439458)
6. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol, 18: 2648-2657, 2000. (Pubitemid 30465650)
7. Borner MM, Schoffski P, De Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, Van der Born K, Wanders J, De Boer RF, Martin C, Fumoleau P: Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer, 38: 349-358, 2002. (Pubitemid 34121962)
8. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol, 19: 2282-2292, 2001. (Pubitemid 32366981)
9. Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol, 15: 110-115, 1997. (Pubitemid 27021524)
10. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer, 34: 1274-1281, 1998. (Pubitemid 28342121)
11. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B: Preferential activation of capecitabine in tumour following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol, 34: 291-297, 2000. (Pubitemid 30151522)
12. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol, 55: 1091-1097, 1998. (Pubitemid 28167730)
13. Ishitsuka H: Capecitabine: preclinical pharmacology studies. Invest New Drugs, 18: 343-354, 2000.
14. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, Kim BS, Lee JS: Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol, 13: 1893-1898, 2002. (Pubitemid 36049952)
15. Kang YK, Kim TW, Chang HM, Ryu MH, Yook JH, Oh ST, Kim BS, Lee JS: A phase I/II trial of docetaxel, capecitabine, and cisplatin as a first line chemotherapy for advanced gastric cancer [abstract]. Proc Am Soc Clin Oncol, 22: s250, 2004.
16. Park YH, Kim BS, Ryoo BY, Yang SH: A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer, 94: 959-963, 2006.
17. Woynarowsk JM, Faivre S, Herzig MC, Woynarowski JM, Faivre S, Herzig M, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE: Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol, 58: 920-927, 2000.
18. Schmidt W, Chaney SG: Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res, 53: 799-908, 1993.
19. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG: Enhanced replicative bypass of platinum- DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res, 54: 3500-3505, 1994. (Pubitemid 24225973)
20. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol, 25: 299-303, 1990. (Pubitemid 20014976)
21. Becouarn Y, Agostini C, TruZandier WK, Boulanger V: Oxaliplatin: available data in non-colorectal gastrointestinal malignancies. Crit Rev Oncol Hematol, 40: 265-272, 2001. (Pubitemid 33111071)
22. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol, 22: 23-30, 2004. (Pubitemid 41095110)
23. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, De Gramont A: Multicenter International Study of Oxaliplatin/ 5-Fluorouracil /Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 350: 2343-2351, 2004.
24. Park YH, Kim BS, Ryoo BY, Yang SH: A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line for patients with advanced gastric cancer. Br J Cancer, 94: 959-963, 2006.
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. Natl Cancer Inst, 92: 205-216, 2000. (Pubitemid 30099779)
26. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials, 1989; 10:1-10.
27. Hu B, Yu JR, Wen ZZ, Shu YQ, Wang BC, Yin HR, Chen L, Bai YX, Liang J, Chen L, Cheng Y, Shen L, Zhou Y, Zhang HG, Li J, Wan DS, Chen S, Jia TZ, Jin ML: Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma: a phase II clinical study. Zhonghua Zhong Liu Za Zhi, 30: 940-943, 2008.
28. Park YH, Lee JL, Ryoo BY, Ryu MH, Yang SH, Kim BS, Shin DB, Chang HM, Kim TW, Yuh YJ: Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol, 61: 623-629, 2008.
29. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol, 20: 666-673, 2009.
30. Cunningham D, Rao S, Starling N, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 358: 36-46, 2008.
31. Jatoi A, Murphy BR, Foster NR, Nikcevich DA, Alberts SR, Knost JA, Fithc TR, Rowlang KM: North Central Cancer Treatment Group: Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol, 17: 29-34, 2006. (Pubitemid 43033836)
32. Al-Batran S, Hartmann J, Probst S, Hofheinz R, Stoehlmacher J, Schmalenberg H, Hollerbach S, Schuch G, Homann N, Jäger E: A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). J Clin Oncol, 24: s18, 2006.
33. Liu CY, Sun Q, Hang XS, Zhong BL, Wang DY: Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patientswith advanced gastric cancer. Anti-Cancer Drugs, 19: 825-831, 2008.
34. Dong NN, Jiang WR, Li HQ, Liu ZF, Xu XQ, Wang MY: Tri-weekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer. Am J Clin Oncol, 32: 559-563, 2009.
35. Luo HY, Xu RH, Wang F, Qiu MZ, Li YH, Li FH: Phase II Trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy, 56: 94-100, 2010.